204 related articles for article (PubMed ID: 24945248)
1. Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain.
Spencer AJ; Cottingham MG; Jenks JA; Longley RJ; Capone S; Colloca S; Folgori A; Cortese R; Nicosia A; Bregu M; Hill AV
PLoS One; 2014; 9(6):e100538. PubMed ID: 24945248
[TBL] [Abstract][Full Text] [Related]
2. Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8
Halbroth BR; Sebastian S; Poyntz HC; Bregu M; Cottingham MG; Hill AVS; Spencer AJ
Sci Rep; 2018 Oct; 8(1):15020. PubMed ID: 30301933
[TBL] [Abstract][Full Text] [Related]
3. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.
Bliss CM; Bowyer G; Anagnostou NA; Havelock T; Snudden CM; Davies H; de Cassan SC; Grobbelaar A; Lawrie AM; Venkatraman N; Poulton ID; Roberts R; Mange PB; Choudhary P; Faust SN; Colloca S; Gilbert SC; Nicosia A; Hill AVS; Ewer KJ
Sci Rep; 2018 Feb; 8(1):3390. PubMed ID: 29467399
[TBL] [Abstract][Full Text] [Related]
4. Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates.
Capone S; Naddeo M; D'Alise AM; Abbate A; Grazioli F; Del Gaudio A; Del Sorbo M; Esposito ML; Ammendola V; Perretta G; Taglioni A; Colloca S; Nicosia A; Cortese R; Folgori A
Mol Ther; 2014 May; 22(5):1039-47. PubMed ID: 24476798
[TBL] [Abstract][Full Text] [Related]
5. Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.
Forbes EK; Biswas S; Collins KA; Gilbert SC; Hill AV; Draper SJ
J Immunol; 2011 Oct; 187(7):3738-50. PubMed ID: 21876036
[TBL] [Abstract][Full Text] [Related]
6. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.
Venkatraman N; Anagnostou N; Bliss C; Bowyer G; Wright D; Lövgren-Bengtsson K; Roberts R; Poulton I; Lawrie A; Ewer K; V S Hill A
Vaccine; 2017 Oct; 35(45):6208-6217. PubMed ID: 28941620
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
Ogwang C; Afolabi M; Kimani D; Jagne YJ; Sheehy SH; Bliss CM; Duncan CJ; Collins KA; Garcia Knight MA; Kimani E; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Spencer AJ; Soipei P; Mueller J; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Gantlett K; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Urban BC; Flanagan KL; Ewer KJ; Chilengi R; Hill AV; Bojang K
PLoS One; 2013; 8(3):e57726. PubMed ID: 23526949
[TBL] [Abstract][Full Text] [Related]
9. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
Draper SJ; Biswas S; Spencer AJ; Remarque EJ; Capone S; Naddeo M; Dicks MD; Faber BW; de Cassan SC; Folgori A; Nicosia A; Gilbert SC; Hill AV
J Immunol; 2010 Dec; 185(12):7583-95. PubMed ID: 21098232
[TBL] [Abstract][Full Text] [Related]
10. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
[TBL] [Abstract][Full Text] [Related]
11. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.
Hodgson SH; Ewer KJ; Bliss CM; Edwards NJ; Rampling T; Anagnostou NA; de Barra E; Havelock T; Bowyer G; Poulton ID; de Cassan S; Longley R; Illingworth JJ; Douglas AD; Mange PB; Collins KA; Roberts R; Gerry S; Berrie E; Moyle S; Colloca S; Cortese R; Sinden RE; Gilbert SC; Bejon P; Lawrie AM; Nicosia A; Faust SN; Hill AV
J Infect Dis; 2015 Apr; 211(7):1076-86. PubMed ID: 25336730
[TBL] [Abstract][Full Text] [Related]
13. Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
Mensah VA; Gueye A; Ndiaye M; Edwards NJ; Wright D; Anagnostou NA; Syll M; Ndaw A; Abiola A; Bliss C; Gomis JF; Petersen I; Ogwang C; Dieye T; Viebig NK; Lawrie AM; Roberts R; Nicosia A; Faye B; Gaye O; Leroy O; Imoukhuede EB; Ewer KJ; Bejon P; Hill AV; Cisse B;
PLoS One; 2016; 11(12):e0167951. PubMed ID: 27978537
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.
Longley RJ; Halbroth BR; Salman AM; Ewer KJ; Hodgson SH; Janse CJ; Khan SM; Hill AVS; Spencer AJ
Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28031267
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites.
Bauza K; Malinauskas T; Pfander C; Anar B; Jones EY; Billker O; Hill AV; Reyes-Sandoval A
Infect Immun; 2014 Mar; 82(3):1277-86. PubMed ID: 24379295
[TBL] [Abstract][Full Text] [Related]
17. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
Kimani D; Jagne YJ; Cox M; Kimani E; Bliss CM; Gitau E; Ogwang C; Afolabi MO; Bowyer G; Collins KA; Edwards N; Hodgson SH; Duncan CJ; Spencer AJ; Knight MG; Drammeh A; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Soipei P; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Chilengi R; Bojang K; Flanagan KL; Hill AV; Urban BC; Ewer KJ
Mol Ther; 2014 Nov; 22(11):1992-2003. PubMed ID: 24930599
[TBL] [Abstract][Full Text] [Related]
18. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
Reyes-Sandoval A; Berthoud T; Alder N; Siani L; Gilbert SC; Nicosia A; Colloca S; Cortese R; Hill AV
Infect Immun; 2010 Jan; 78(1):145-53. PubMed ID: 19858306
[TBL] [Abstract][Full Text] [Related]
19. A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates.
Padte NN; Boente-Carrera M; Andrews CD; McManus J; Grasperge BF; Gettie A; Coelho-dos-Reis JG; Li X; Wu D; Bruder JT; Sedegah M; Patterson N; Richie TL; Wong CH; Ho DD; Vasan S; Tsuji M
PLoS One; 2013; 8(10):e78407. PubMed ID: 24205224
[TBL] [Abstract][Full Text] [Related]
20. Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines.
Dobaño C; Rogers WO; Gowda K; Doolan DL
Immunol Lett; 2007 Aug; 111(2):92-102. PubMed ID: 17604849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
